Clinical Trials Logo

Leiomyoma clinical trials

View clinical trials related to Leiomyoma.

Filter by:

NCT ID: NCT02655237 Completed - Uterine Fibroids Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Start date: March 5, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time) in patients with uterine fibroids.

NCT ID: NCT02655224 Completed - Uterine Fibroids Clinical Trials

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Start date: March 26, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.

NCT ID: NCT02654054 Completed - Uterine Fibroids Clinical Trials

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Start date: December 22, 2015
Phase: Phase 3
Study type: Interventional

This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

NCT ID: NCT02620345 Completed - Fibroids Clinical Trials

Fibroids in Women of Reproductive Age and Women Pregnancy

Fibroids
Start date: January 2010
Phase: Phase 4
Study type: Interventional

Dydrogesterone Multivitamin Nature treatment of fibroids in women of reproductive age and women pregnancy to lost the size fibroids.

NCT ID: NCT02580578 Completed - Leiomyoma Clinical Trials

A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids

Start date: July 31, 2015
Phase:
Study type: Observational

This study will characterize the treatments and outcomes associated with different uterine fibroid treatments in Canada, to understand patients' preferences and satisfaction with different medical and procedural interventions. The study will also assess the effectiveness of ulipristal acetate (Fibristal®) in controlling bleeding, reducing fibroid volume and symptoms, and improvement in patient's quality of life.

NCT ID: NCT02577055 Completed - Leiomyoma Clinical Trials

Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids

Lune2
Start date: April 2016
Phase: N/A
Study type: Interventional

Purpose of this study: To establish the superiority of myomectomy versus Uterine Artery Embolization, in women with multiple symptomatic fibroids and no other infertility factor, seeking to conceive.

NCT ID: NCT02520414 Completed - Uterine Leiomyomas Clinical Trials

Symphion® System In-Office Study

Start date: November 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of using the Symphion system in an office setting.

NCT ID: NCT02472184 Completed - Uterine Fibroids Clinical Trials

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

Start date: October 2015
Phase: N/A
Study type: Interventional

This study will look at the optimal order in which to perform concurrent office hysteroscopy and endometrial biopsy in female patients who present for evaluation of abnormal uterine bleeding at a fibroid and endometriosis treatment center.

NCT ID: NCT02470741 Completed - Uterine Fibroids Clinical Trials

Pilot of Letrozole for Uterine Myomas

PLUM
Start date: July 2015
Phase: Phase 4
Study type: Interventional

PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day for 6 months (Group A) or intermittent dosing with letrozole 2.5mg/day and an identical placebo capsule (Group B).

NCT ID: NCT02465814 Completed - Leiomyoma Clinical Trials

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

ASTEROID 2
Start date: June 2015
Phase: Phase 2
Study type: Interventional

The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with uterine fibroids compared to placebo and ulipristal. It is also aimed to evaluate the safety of vilaprisan in subjects with uterine fibroids. Further, data on population pharmacokinetic (PK)/ pharmacodynamic (PD) relationship for vilaprisan in subjects with uterine fibroids will be supplemented.